The pharmaceuticals company, which is backed by investors including corporate venturing funds from GlaxoSmithKline and AstraZeneca, has filed for an initial public offering which could raise up to $80m.
US-based broad spectrum antibiotics developer Rib-X Pharmaceuticals filed for an initial public offering (IPO) on Monday, and is looking to raise up to $80m.
Shareholders in Rib-X include SR One, the corporate venturing unit belonging to healthcare conglomerate GlaxoSmithKline which holds 7.4% of Rib-X’s common stock, and MedImmune Ventures, a corporate venture fund operated by pharmaceuticals company AstraZeneca (which holds 6.0%).
Also holding stock in Rib-X are private equity (PE) firm Warburg Pincus (45%), and venture capital (VC) firms…
